News
Krebsforschung: Neue Immuntherapie für BlutkrebskrankeKleine Zeitung
www.kleinezeitung.at
— Der Münchener Immunologe Peter Kufer erforschte ein mögliches Wirkprinzip gegen Krebs, das andere Forscher bereits aufgegeben hatten — Der Münchener Immunologe Peter Kufer erforschte ein mögliches Wirkprinzip gegen Krebs, das andere Forscher bereits aufgegeben hatten.
onkoserv - der aktuellste und unabhängige deutsche Informationsdienst...
www.onkoserv.de
Onkoserv ist der aktuellste deutsche Informationsdienst für die klinische Onkologie
Amgen's Highest Honor Awarded to Peter Kufer for BiTE® Technologywww.amgen.com › stories › › amgens-high...
www.amgen.com
· Peter Kufer, vice president of BiTE® technology and site head of Amgen Research Munich (ARM), recently became one of the select few in ...
Antikörper-Partikel bringen Krebs- und Immunzellen in engen Kontakt
www.aerztezeitung.de
Mit bispezifischen Antikörpern, die Immun- und Krebszelle gleichzeitig erkennen, dürften sich künftig einige der Limitierungen der herkömmlichen Immuntherapie...
Netzwerk-Profile
LinkedIn: de.linkedin.com
Sehen Sie sich das Profil von Peter Kufer auf LinkedIn an. Als weltweit größtes Business-Netzwerk hilft LinkedIn Menschen wie Peter Kufer dabei, ...
Interessen
Peter Kufer - Patents
www.freshpatents.com
Recent bibliographic sampling of Peter Kufer patents listed/published in the public domain by the USPTO (USPTO Patent Application #,Title):
A revival of bispecific antibodiesCell Press
www.cell.com
Peter Kufer, Ralf Lutterbüse, Patrick A. Baeuerle. Trends in Biotechnology. Volume 22 Issue 5 Pages (May 2004). DOI: j.tibtech Peter Kufer, Ralf Lutterbüse, Patrick A. Baeuerle. Trends in Biotechnology. Volume 22 Issue 5 Pages (May 2004). DOI: j.tibtech
Firmen-Mitarbeiter
Blinatumomab Breakthrough drug emerges for B-cell ALL
www.astp4kt.eu
After decades of research, scientists have discovered a drug that engages the immune system to fight B-precursor acute lymphoblastic leukemia, a rare and...
Private Homepages
Peter Kufer Namen Analyse
peter-kufer.deunamen.com
DeuNamen.com - Peter Kufer Namen Analyse und statistische für Deutschland und Österreich
About - Peter KuferDiscovery Medicine
www.discoverymedicine.com
Peter Kufer. Institution: Micromet AG Address: MunichGermany. Content of this page is coming. Email This | Share This. Peter Kufer. Institution: Micromet AG Address: MunichGermany. Content of this page is coming. Email This | Share This.
Novel BiTE antibody mediates contact between T cells and ...
www.cancernetwork.com
— ... said Peter Kufer, MD, PhD, vice president of immunotherapy at Micromet, who reported the feasibility of this approach (abstracts › ...
Promis, Sportler & Politiker
IMDB Filmographie: Peter Küfer
Actor, Timeless
IMDB Filmographie: Innovation Squared (TV Series 2021– ) - Peter Kufer as SelfIMDb
Peter Kufer: Self. It looks like we don't have any photos or quotes yet. Be the first to contribute! Add a photo or add a quote. See also. Release Dates ... Peter Kufer: Self. It looks like we don't have any photos or quotes yet. Be the first to contribute! Add a photo or add a quote. See also. Release Dates ...
Herkunft
Anna Kufer - Historical records and family trees - MyHeritagewww.myheritage.com › names › anna_kufer
www.myheritage.com
Anna married Peter Kufer on month day 1764, at age 14 at marriage place, Pennsylvania. Peter was born in 1740, in Berwangen, Kirchardt, Heidelberg, Baden, ...
Projekte
M22
www.hector-stiftung.de
1, 2002; Ingo Mecklenburg, Dorothea Weckermann, Alfred Zippelius, Alexandra Schoberth, Stephanie Petersen, Nadja Prang, Gert Riethmüller, Peter Kufer A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized ...
Bücher
Bispecific T cell engaging antibody constructs UGent BiblioUGent Biblio
biblio.ugent.be
von J Pendzialek · · Zitiert von: 20 — Pendzialek, Jochen, Kenny Roose, Anouk Smet, Bert Schepens, Peter Kufer, Tobias Raum, Patrick A Baeuerle, Markus Muenz, Xavier Saelens, and ... von J Pendzialek · · Zitiert von: 20 — Pendzialek, Jochen, Kenny Roose, Anouk Smet, Bert Schepens, Peter Kufer, Tobias Raum, Patrick A Baeuerle, Markus Muenz, Xavier Saelens, and ...
Dr. Peter Kufer, Vice President & Innovator of BITE Technology ...www.onclive.com › authors › dr-peter-kufer-vice-pr...
www.onclive.com
· Dr. Peter Kufer, Vice President & Innovator of BITE Technology, Amgen Sponsored by Amgen Oncology. home / authors / dr-peter-kufer ...
AACR Proceedings: Abstracts American Association for...
books.google.de
The AACR Annual Meeting highlights the best cancer science and medicine from institutions all over the world. Attendees are invited to stretch their...
Appendix to ... Journals of the Legislative Assembly of the ...
books.google.de
Peter Kufer David Chisholm , Guy C. Colclough , William Jones , | Thomas Neill , Plantagenet , do Outaouais , .
Dokumente zum Namen
Recombinant CD4‐IgE, a novel hybrid molecule, inducing ...Wiley Online Library
onlinelibrary.wiley.com
von S Krauss · · Zitiert von: 13 — ... Peter Kufer,. Peter Kufer. Institute for Immunology, University of Munich, Munich. Search for more papers by this author · Christine Federle,. Christine Federle. von S Krauss · · Zitiert von: 13 — ... Peter Kufer,. Peter Kufer. Institute for Immunology, University of Munich, Munich. Search for more papers by this author · Christine Federle,. Christine Federle.
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
... Marie-Elisabeth Goebeler, Barbara Ritter, Alexander Quaas, Eva Vieser, Youssef Hijazi, Ingrid Patzak, Matthias Friedrich, Peter Kufer, Stanley Frankel, ... › ab...
The BiTE (bispecific T‐cell engager) platform: Development ...Wiley
acsjournals.onlinelibrary.wiley.com
von H Einsele · · Zitiert von: 151 — Peter Kufer is an employee of Amgen Inc and holds stock in the company; in addition, he issued and licensed patients for Blinatumomab and CD von H Einsele · · Zitiert von: 151 — Peter Kufer is an employee of Amgen Inc and holds stock in the company; in addition, he issued and licensed patients for Blinatumomab and CD
Abstract - ASCO MeetingAmerican Society of Clinical Oncology (ASCO)
meetings.asco.org
... Peter Kufer, Andreas Wolf, Dirk Nagorsen. Organizations. Amgen Research (Munich) GmbH, Munich, Germany, Pharmacokinetics & Drug Metabolism, Amgen Inc Peter Kufer, Andreas Wolf, Dirk Nagorsen. Organizations. Amgen Research (Munich) GmbH, Munich, Germany, Pharmacokinetics & Drug Metabolism, Amgen Inc ...
Wissenschaftliche Veröffentlichungen
Patents Assigned to Amgen Research (Munich) GmbHJustia
patents.justia.com
Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC. Inventors: Tobias Raum, Jonas Anlahr, Julie Bailis, Claudia Blümel, Patrick Hoffmann, Peter Kufer, Elisabeth ... Assignees: AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC. Inventors: Tobias Raum, Jonas Anlahr, Julie Bailis, Claudia Blümel, Patrick Hoffmann, Peter Kufer, Elisabeth ...
Dr. Peter Kufer - GEPRIS - DFGDFG - GEPRIS
gepris.dfg.de
Dr. Peter Kufer, Forschungsbereich ImmunologiePlanegg. Dr. Peter Kufer, Forschungsbereich ImmunologiePlanegg.
Bispecific T cell engaging antibody constructs targeting a ...ScienceDirect.com
www.sciencedirect.com
von J Pendzialek · · Zitiert von: 20 — , Kenny Roose b c 1 , Anouk Smet b c , Bert Schepens b c , Peter Kufer a , Tobias Raum a , Patrick A. Baeuerle a , Markus Muenz a 2 , Xavier Saelens b c 2 von J Pendzialek · · Zitiert von: 20 — , Kenny Roose b c 1 , Anouk Smet b c , Bert Schepens b c , Peter Kufer a , Tobias Raum a , Patrick A. Baeuerle a , Markus Muenz a 2 , Xavier Saelens b c 2
Side-by-side analysis of five clinically tested anti-EpCAM ...
cancerci.biomedcentral.com
von M Münz · · Zitiert von: 110 — ... Stefan Pflanz, John Lumsden, Jörg Volkland, Jan Fagerberg, Dominik Rüttinger, Peter Kufer, Patrick A Baeuerle & Tobias Raum. › ...
Veröffentlichungen allgemein
Heterogeneous Expression of MAGE-A Genes in Cancer Research
www.yumpu.com
Heterogeneous Expression of MAGE-A Genes in Cancer Research
Anti-self antibodies selected from a human IgD heavy chain...
link.springer.com
Human antibodies were isolated by phage display from a naturally expressed human antibody repertoire. Antibody selection was carried out against the epithe
BiTE® Plattform hat solide Tumore im VisierPresseportal
www.presseportal.de
— Peter Kufer, Geschäftsführer der Amgen Research (Munich) GmbH. "Wesentliche Standortfaktoren sind die deutsche Hochschullandschaft und gut — Peter Kufer, Geschäftsführer der Amgen Research (Munich) GmbH. "Wesentliche Standortfaktoren sind die deutsche Hochschullandschaft und gut ...
A bispecific single-chain antibody directed against EpCAM/ ...Springer
link.springer.com
von D Flieger · · Zitiert von: 48 — Dimitri Flieger, · Peter Kufer, · Imke Beier, · Tilman Sauerbruch & ·… · Ingo G. H. Schmidt-Wolf. von D Flieger · · Zitiert von: 48 — Dimitri Flieger, · Peter Kufer, · Imke Beier, · Tilman Sauerbruch & ·… · Ingo G. H. Schmidt-Wolf.
Video & Audio
Innovation Squared: What does it take to be innovative? (Dr Peter...
www.youtube.com
Innovation Squared is a video series featuring Amgen employees around the world talking to inspiring people from other fields about innovation, science and r...
Innovation Squared: Ep 4 | It Takes Tenacity - YouTubeYouTube · Amgen + Aufrufe · vor 2 Jahren
www.youtube.com
... Peter Kufer, Vice President and Innovator of BiTE® Technology at Amgen, and Dr. David Putrino, Director of Rehabilitation Innovation at ...
Artikel & Meinungen
Twitter-Nachrichten: Amgen OncologyX
Peter Kufer, vice president of BiTE® technology and site head of Amgen Research Munich, recently became one of the select few in Amgen's history to receive ... Peter Kufer, vice president of BiTE® technology and site head of Amgen Research Munich, recently became one of the select few in Amgen's history to receive ...
Cellular and complement-dependent cytotoxicity of Ep-CAM-specific...
www.nature.com
Molecular Diagnostics
Sonstiges
linkedin.com
www.linkedin.com
Congrats to my Munich-based Amgen R&D colleague Peter Kufer for receipt of Amgen's Rathmann Award — recognizing Peter's pioneering ...
linkedin.com
www.linkedin.com
Huge congratulations to my colleague Peter Kufer on receiving the George B. Rathmann Award for Scientific Excellence – the highest honor ...
linkedin.com
www.linkedin.com
Peter Kufer, vice president of BiTE® technology and site head of Amgen Research Munich, recently became one of the select few in Amgen's ...
linkedin.com
www.linkedin.com
Peter Kufer, vice president of BiTE® technology and site head of Amgen Research Munich, recently became one of the select few in Amgen's ...
linkedin.com
www.linkedin.com
Peter Kufer, vice president of BiTE® technology and site head of Amgen Research Munich, recently became one of the select few in Amgen's ...
linkedin.com
www.linkedin.com
Peter Kufer, vice president of BiTE® technology and site head of Amgen Research Munich, recently became one of the select few in Amgen's ...
Amgen's Highest Honor Awarded to Peter Kufer for BiTE® ...linkedin.com
www.linkedin.com
Peter Kufer, vice president of BiTE® technology and site head of Amgen Research Munich, recently became one of the select few in Amgen's ... Peter Kufer, vice president of BiTE® technology and site head of Amgen Research Munich, recently became one of the select few in Amgen's ...
US B2 - BCMA and CD3 bispecific T cell engaging ...patents.google.com › patent
patents.google.com
... Other versions: US A1 (en; Inventor: Tobias Raum: Markus Münz: Johannes Brozy: Peter Kufer: Patrick Hoffmann: Matthias Friedrich: Benno Rattel ...
Handelsregisterauszug von Peter Kufer aus München (HRA 9811)
www.online-handelsregister.de
Handelsregisterauszug der Peter Kufer aus München sofort und ohne Wartezeit als PDF herunterladen
Peter Kufer Erfahrungen - BewertungenGoWork DE
gowork.de
Sehen Sie sich die Bewertungen zu Peter Kufer Deutschland an. Verdienstforum, Informationen zu Gehältern, Vorgesetzten, Umwelt, Stellenangeboten, Adressen,. Sehen Sie sich die Bewertungen zu Peter Kufer Deutschland an. Verdienstforum, Informationen zu Gehältern, Vorgesetzten, Umwelt, Stellenangeboten, Adressen,.
Peter Kufer - Entity | RPX Insight
insight.rpxcorp.com
Peter Kufer has 0 patent litigation cases (0 cases currently active) - 0 patents asserted - 0 cases as a plaintiff - 0 cases as a defendant.
Peter Kufer: Inventor, BLINCYTOIPO Education Foundation
www.ipoef.org
— Peter Kufer, Executive Director, BiTE® Technology at Amgen, led the academic research group that innovated the BiTE® (i.e., bispecific T cell — Peter Kufer, Executive Director, BiTE® Technology at Amgen, led the academic research group that innovated the BiTE® (i.e., bispecific T cell ...
Peter Kufer in München | Firma
firma-online.org
Hier alle Infos zu Adresse, Inhaber, Branche, Kontakt oder Alter finden: Firma Peter Kufer in , München, Bayern
Search for "Kufer,+Peter,+Moosburg"
www.northdata.com
Company publications and network for Peter Kufer, Moosburg, Germany: Amgen Research (Munich) GmbH.
Peter Kufer (peterkufer6967) - ProfilePinterest - Deutschland
www.pinterest.de
P. Peter Kufer. peterkufer Follower. ·. 0 folge ich. Folgen. peterkufer6967 hat sich noch keine Pins gemerkt. P. Peter Kufer. peterkufer Follower. ·. 0 folge ich. Folgen. peterkufer6967 hat sich noch keine Pins gemerkt.
Zehentfixation des Peter Kufer von NiederhatzkofenArchivportal-D
www.archivportal-d.de
Zehentfixation des Peter Kufer von Niederhatzkofen ; Verzeichnungsstufe: Archivale ; Archivaliensignatur: Staatsarchiv Landshut, Landgericht ä.O. Rottenburg Zehentfixation des Peter Kufer von Niederhatzkofen ; Verzeichnungsstufe: Archivale ; Archivaliensignatur: Staatsarchiv Landshut, Landgericht ä.O. Rottenburg 124.
Peter Kufer, Moosburg - North Datawww.northdata.de › Personen › Moosburg
www.northdata.de
Firmenbekanntmachungen und Netzwerk zu Peter Kufer, Moosburg: Amgen Research (Munich) GmbH.
Peter Kufer, Moosburg DE - Patent applications
www.patentsencyclopedia.com
Patent application number, Description, Published , Less Immunogenic Binding Molecules - The present invention provides a bispecific binding ...
Peter Kufer, Munich DE - Patent applications
www.patentsencyclopedia.com
Patent application number, Description, Published , BISPECIFIC ANTIBODIES - The present invention discloses bispecific antibodies comprising ...
sortiert nach Relevanz / Datum